REP. WAXMAN's SYNTHETIC HUMAN GROWTH HORMONE BILL
REP. WAXMAN's SYNTHETIC HUMAN GROWTH HORMONE BILL was moved to the House on Oct. 17, after it had been placed on the House floor calendar. Introduced on Oct. 6 & 10, the measure would require Schedule II controls of somatrem (Genetech's Protropin) and all other synthetic growth hormone products under the Controlled Substances Act. The California Democrat told the House his legislation would "provide appropriate safeguards against the deliberate and potentially life-threatening abuse of this product . . . while scientific research continues." The bill is not expected to clear the House. The bill would not "limit the proper use of this drug, nor would it inhibit necessary research," he added. The legislation is aimed at use of the drug to enhance size and strength by athletes. The potential harm from such use has not been documented with somatrem, as it has with anabolic steroids. The drug is therapeutically indicated for dwarfism in children. Waxman's legislation was expected to meet with opposition in the Senate. Protropinmanufacturer Genentech opposed the bill. The company told "The Pink Sheet" that the bill would increase costs for consumers by requiring repeated physician visits because Schedule II Rx drugs are not refillable. In addition, the company maintained, the recordkeeping requirements of the Drug Enforcement Administration (DEA) controls would place an unnecessary burden on physicians and manufacturers of synthetic growth hormones. Finally, Genentech said, decisions on Rx drug controls are properly made by FDA and DEA rather than the Congress. The company contended that there are no similarities between Protropin and Schedule II drugs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth